Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma

Ciaran O'Neill, Peter G. Gibson, Liam G. Heaney, John W. Upham, Ian A. Yang, Paul N. Reynolds, Sandra Hodge, Christine R. Jenkins, Matthew Peters, Guy B. Marks, Alan L. James, Jodie L. Simpson
European Respiratory Journal 2021 57: 2002436; DOI: 10.1183/13993003.02436-2020
Ciaran O'Neill
1Centre for Public Health, Queen's University Belfast, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter G. Gibson
2Priority Research Centre for Healthy Lungs, Faculty of Health and Medicine, Hunter Medical Research Institute and University of Newcastle, Newcastle, Australia
3Dept of Respiratory and Sleep Medicine, Hunter New England Area Health Service, John Hunter Hospital, Newcastle, NSW Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liam G. Heaney
4Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John W. Upham
5Faculty of Medicine, The University of Queensland, St Lucia, Australia
6Translational Research Institute, Princess Alexandra Hospital, Woolloongabba, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian A. Yang
5Faculty of Medicine, The University of Queensland, St Lucia, Australia
7Dept of Thoracic Medicine, The Prince Charles Hospital, Chermside, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul N. Reynolds
8School of Medicine, The University of Adelaide, Adelaide, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Hodge
9Dept of Thoracic Medicine, Lung Research Unit, Royal Adelaide Hospital, Adelaide, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine R. Jenkins
10Respiratory Trials, The George Institute for Global Health, Sydney, Australia
11Dept of Thoracic Medicine, Concord General Hospital, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christine R. Jenkins
Matthew Peters
11Dept of Thoracic Medicine, Concord General Hospital, Sydney, Australia
12Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guy B. Marks
13Woolcock Institute of Medical Research, Sydney, Australia
14South Western Sydney Clinical School, University of New South Wales, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Guy B. Marks
Alan L. James
15Medical School, University of Western Australia, Crawley, Australia
16Dept of Pulmonary Physiology and Sleep Medicine, Sir Charles Gairdner Hospital, Nedlands, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jodie L. Simpson
2Priority Research Centre for Healthy Lungs, Faculty of Health and Medicine, Hunter Medical Research Institute and University of Newcastle, Newcastle, Australia
3Dept of Respiratory and Sleep Medicine, Hunter New England Area Health Service, John Hunter Hospital, Newcastle, NSW Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Add-on azithromycin (AZM) results in a significant reduction in exacerbations among adults with persistent uncontrolled asthma. The aim of this study was to assess the cost-effectiveness of add-on AZM in terms of healthcare and societal costs.

The AMAZES trial randomly assigned 420 participants to AZM or placebo. Healthcare use and asthma exacerbations were measured during the treatment period. Healthcare use included all prescribed medicine and healthcare contacts. Costs of antimicrobial resistance (AMR) were estimated based on overall consumption and published estimates of costs. The value of an avoided exacerbation was based on published references. Differences in cost between the two groups were related to differences in exacerbations in a series of net monetary benefit estimates. Societal costs included lost productivity, over the counter medicines, steroid induced morbidity and AMR costs.

Add-on AZM resulted in a reduction in healthcare costs (mean (95% CI)) including nights in hospital (AUD 433.70 (AUD 48.59–818.81) or EUR 260.22 (EUR 29.15–491.29)), unplanned healthcare visits (AUD 20.25 (AUD 5.23–35.27) or EUR 12.15 (EUR 3.14–21.16)), antibiotic costs (AUD 14.88 (AUD 7.55–22.21) or EUR 8.93 (EUR 4.53–13.33)) and oral corticosteroid costs (AUD 4.73 (AUD 0.82–8.64) or EUR 2.84 (EUR 0.49–5.18)); all p<0.05. Overall healthcare and societal costs were lower (AUD 77.30 (EUR 46.38) and AUD 256.22 (EUR 153.73) respectively) albeit not statistically significant. The net monetary benefit of add-on AZM was estimated to be AUD 2072.30 (95% CI AUD 1348.55–2805.23) or (EUR 1243.38 (EUR 809.13–1683.14) assuming a willingness to pay per exacerbation avoided of AUD 2651 (EUR 1590.60). Irrespective of the sensitivity analysis applied, the net monetary benefit for total, moderate and severe exacerbations remained positive and significant.

Add-on AZM therapy in poorly controlled asthma was a cost-effective therapy. Costs associated with AMR did not influence estimated cost-effectiveness.

Abstract

Add-on AZM in the treatment of poorly controlled persistent asthma is cost-effective. It is associated with a positive net monetary benefit when costs including those associated with antimicrobial resistance are considered. https://bit.ly/31aZ3fi

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • This study is registered at the Australian and New Zealand Clinical Trials Registry (ANZCTR), number 12609000197235.

  • Conflict of interest: C. O'Neill reports grants for education activities from Roche, AbbVie, Novartis and Pfizer, outside the submitted work.

  • Conflict of interest: P.G. Gibson reports personal fees for lectures from AstraZeneca, GlaxoSmithKline and Novartis, grants from AstraZeneca and GlaxoSmithKline, outside the submitted work.

  • Conflict of interest: L.G. Heaney reports sponsorship for meeting attendance from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Napp Pharmaceutical, personal fees for advisory board work and lectures from Novartis, Hoffman la Roche/Genentech Inc, Sanofi, GlaxoSmithKline, AstraZeneca, Teva, Theravance and Circassia, grants from Medimmune, Novartis UK, Roche/Genentech Inc. and GlaxoSmithKline, and Amgen, outside the submitted work; and is Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma, which involves industrial partnerships with Genentech/Hoffman la Roche, AstraZeneca, Medimmune, GlaxoSmithKline, Aerocrine and Vitalograph.

  • Conflict of interest: J.W. Upham reports grants from NHMRC, during the conduct of the study.

  • Conflict of interest: I.A. Yang reports grants from NHMRC, during the conduct of the study.

  • Conflict of interest: P.N. Reynolds reports grants from NHMRC, during the conduct of the study.

  • Conflict of interest: S. Hodge reports grants from NHMRC, during the conduct of the study.

  • Conflict of interest: C.R. Jenkins reports grants from NHMRC, during the conduct of the study.

  • Conflict of interest: M. Peters reports grants from NHMRC, during the conduct of the study.

  • Conflict of interest: G.B. Marks reports grants from NHMRC, during the conduct of the study; grants and advisory board work from AstraZeneca, grants from GSK, outside the submitted work.

  • Conflict of interest: A.L. James reports grants from NHMRC, during the conduct of the study.

  • Conflict of interest: J.L. Simpson reports grants from NHMRC, during the conduct of the study.

  • Support statement: This work was supported by the National Health and Medical Research Council. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received June 21, 2020.
  • Accepted August 13, 2020.
  • Copyright ©ERS 2021
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 2 Table of Contents
European Respiratory Journal: 57 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma
Ciaran O'Neill, Peter G. Gibson, Liam G. Heaney, John W. Upham, Ian A. Yang, Paul N. Reynolds, Sandra Hodge, Christine R. Jenkins, Matthew Peters, Guy B. Marks, Alan L. James, Jodie L. Simpson
European Respiratory Journal Feb 2021, 57 (2) 2002436; DOI: 10.1183/13993003.02436-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma
Ciaran O'Neill, Peter G. Gibson, Liam G. Heaney, John W. Upham, Ian A. Yang, Paul N. Reynolds, Sandra Hodge, Christine R. Jenkins, Matthew Peters, Guy B. Marks, Alan L. James, Jodie L. Simpson
European Respiratory Journal Feb 2021, 57 (2) 2002436; DOI: 10.1183/13993003.02436-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Allergen inhalation associated with airway dysfunction
  • OSTEOPOROSIS AND FACTURE RISK ASSOCIATED WITH ICS USE IN COPD
Show more Original Articles

Asthma

  • Complement C3 and allergic asthma
  • Identifying asthma phenotypes based on extrapulmonary traits
Show more Asthma

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society